The use of the leukotriene receptor antagonist montelukast (singulair®) in the management of dysmenorrhea in adolescents☆

摘要: Abstract Purpose Previous studies have shown an increase in leukotrienes the uterine tissue as well menstrual flow of adult women with dysmenorrhea. An leukotriene-E4, major urinary leukotriene, was also reported adolescent girls dysmenorrhea, further suggesting a possible involvement these potent vasoconstrictors and inflammatory mediators generating dysmenorrhea symptoms. In present study we examined whether blocking might alleviate symptoms adolescents. Methods Twenty-five adolescents (age 16 ± 1 years, 4 years post menarche, body mass index 23 1) participated randomized, double blind, crossover study. Thirteen received one tablet montelukast (Singulair ® , Merck, West Point, PA) 10 mg daily starting on day 21 cycle until last period for two cycles, followed by placebo (Merck, additional cycles. The other 12 had reverse schedule placebo. Participants were instructed to use or 200-mg tablets ibuprofen every 6 h event continuing Cox Menstrual Symptom Scale used assess response treatment. intent-to-treat approach data analysis. Results Twenty-two completed Two noncompliant protocol, withdrawn because Helicobacter pylori infection. Compared score (mean SE) before (46 6), there no significant change during treatment (Cox 42 7) 39 7), difference between treatments well. Likewise, amount consumed periods (4 1), while (3 1). Conclusions This does not support montelukast, current FDA-approved dose (for asthma) commencing immediately period, It remains be determined higher prolonged may